gonorrhea and chlamydia david h. martin, md lsu health sciences center section of infectious...
TRANSCRIPT
![Page 1: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/1.jpg)
Gonorrhea and Chlamydia
David H. Martin, MD
LSU Health Sciences Center
Section of Infectious Diseases
![Page 2: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/2.jpg)
Disclosure
• I have no financial interests or other relationship with manufacturers of commercial products, suppliers of commercial services, or commercial supporters. My presentation will not include any discussion of the unlabeled use of a product or a product under investigational use.
![Page 3: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/3.jpg)
An STD About to Happen!
![Page 4: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/4.jpg)
Cell Monolayer Infected with Chlamydia and Stained with Chlamydia Specific
Fluorescent Antibodies
Cell cytoplasma counter stained red
Chlamydial inclusions stained apple green
![Page 5: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/5.jpg)
![Page 6: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/6.jpg)
Electron Micrograph of a Chlamydia Infected Endocervix
Chlamydial inclusion
Microabscess
Columnar epithelial cells
![Page 7: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/7.jpg)
![Page 8: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/8.jpg)
Gonococcal Urethritis
![Page 9: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/9.jpg)
Gram Negative Intracellular Diplococci (GNID)
![Page 10: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/10.jpg)
Nongonococcal Urethritis
![Page 11: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/11.jpg)
Inflammation Without GNID
![Page 12: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/12.jpg)
Etiology of Nongonococcal Urethritis - 2002
Chlamydia trachomatis 20-40%
Ureaplasma urealyticum 20-40% ?
Mycoplasma genitalium 20-25%
Trichomonas vaginalis 1-5%
Herpes simplex virus <1%
![Page 13: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/13.jpg)
Epidydimitis
Discharge
Scrotal erythema
![Page 14: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/14.jpg)
![Page 15: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/15.jpg)
Gonococcal Endocervicitis
![Page 16: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/16.jpg)
Chlamydial Endocervicitis
![Page 17: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/17.jpg)
![Page 18: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/18.jpg)
Etiology of PID
1. N. gonorrhoeae 20-40%
2. C. trachomatis 20%
3. Mixed aerobes and anaerobes including Mycooplama hominis + N. gonorrhoeae 40-60%
![Page 19: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/19.jpg)
Diagnosis of PID
History
1. Lower abdominal pain of less than 15 days duration
2. Constant pain
3. Onset within 7 days of menstruation
4. Fever and/or chills
5. Sexual history
![Page 20: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/20.jpg)
Diagnosis of PID
Signs
1. Bilateral adnexal tenderness
2. Cervical motion pain
3. Adnexal mass
4. Endocervical discharge
5. IUD
![Page 21: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/21.jpg)
![Page 22: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/22.jpg)
Maternal Chlamydial Infection
65%
of infants are infected
30 – 50%
of infants develop conjunctivitis
5%of infants develop
pneumonia
![Page 23: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/23.jpg)
Proportion of Chlamydial and Gonococcal Infections that are Asymptomatic
Women Men
C. trachomatis 80-90% 70-80%
N. gonorrhoeae 50-70% 20-30%
![Page 24: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/24.jpg)
Epidemiology
![Page 25: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/25.jpg)
U.S. Gonorrhea Rates: 1970–2000
Rate (per 100,000 population)
Gonorrhea2010 Objective
0
100
200
300
400
500
1970 73 76 79 82 85 88 91 94 97 2000
![Page 26: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/26.jpg)
Chlamydia — Trends in positivity among 15-44 year old women tested in
family planning clinics, 1988–2000
REGION=I
REGION=II
REGION=III
REGION=IV
REGION=IX
REGION=V
REGION=VIREGION=VII
REGION=VIII
REGION=X
6.7
4.9 4.6 4.14.9
96 97 98 99 00
5.7 6.2 6.2 6.4
97 98 99 00
7.46.0
5.3 5.6 6.0 6.3 6.0
94 95 96 97 98 99 00
8.910.1 9.5
8.6
97 98 99 00
5.1 5.25.9 6.3 6.2
96 97 98 99 00
5.6
7.5 7.2 7.1
97 98 99 00
8.4 8.99.7
8.7 8.8
96 97 98 99 00
4.9 4.7 5.4 5.3 5.5
96 97 98 99 00
6.05.0 4.6 4.6
5.3 5.4 5.6
94 95 96 97 98 99 00
13.0
10.0 9.58.0
6.7
5.0 4.7 4.1 3.9 3.94.6 4.9 5.3
88 89 90 91 92 93 94 95 96 97 98 99 00
![Page 27: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/27.jpg)
![Page 28: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/28.jpg)
Diagnosis
![Page 29: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/29.jpg)
Gram Negative Intracellular Diplococci (GNID)
![Page 30: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/30.jpg)
One Step Methylene Blue Stain
![Page 31: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/31.jpg)
Performance of Culture for N. gonorrhoeae and C. trachomatis
Sensitivity Specificity
N. gonorrhoeae 80-90% 100%*
C. trachomatis 60-85% 100%*
*Assuming no mistakes are made in specimen labeling and laboratory procedures.
![Page 32: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/32.jpg)
Cell Monolayer Infected with Chlamydia and Stained with Chlamydia Specific
Fluorescent Antibodies
Cell cytoplasma counter stained red
Chlamydial inclusions stained apple green
![Page 33: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/33.jpg)
Chlamydia Test Sensitivity and Specificity Estimates for Endocervical Specimens
Assay Sensitivity Specificity
Culture 65-80% 99.5%
Antigen detection 50-60% 98%
Gen-Probe 60-70% 98-99%
Amplification 80-90% 99.5%
![Page 34: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/34.jpg)
Performance of the Pace 2 Gonococcal DNA Hybridization Assay in Women
Sensitivity Specificity
Range of 10 studies 85-100% 96-99%
Mean 92.1% 98.3%
![Page 35: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/35.jpg)
![Page 36: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/36.jpg)
![Page 37: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/37.jpg)
Chlamydia Test Sensitivity and Specificity Estimates for Endocervical Specimens
Assay Sensitivity Specificity
Culture 65-80% 99.5%
Antigen detection 50-60% 98%
Gen-Probe 60-70% 98-99%
Amplification 80-90% 99.5%
![Page 38: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/38.jpg)
A Systematic Review of NAAT Sensitivity Using Urine, Cervical and Urethral
Specimens for Chlamydial Infections
Assay Type
Women Men
Urine Cervix Urine Urethra
PCR 83% 86% 84% 88%
TMA 92% 99% 88% 96%
SDA 80% 99% 93% 92%
PCR-polymerase chain reaction. TMA-transcription mediated amplification. SDA-strand displacement amplification.
Cook RL, et al. Annals Int Med. 2005; 142: 914
![Page 39: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/39.jpg)
Performance of an Amplification Test for the Detection of N. gonorrhoeae in Endocervical,
Male Urethra and Urine Specimens
Sensitivity* Specificity
Endocervical 97% 99.7%
Male urethra 99% 99.9%
Female urine 96% 100%
Male urine 98% 100%
*True positive defined as positive endocervical or urethral culture or LCR and alternative gene target positive by LCR
Koumans EH, et al. Clin Infect Dis 1998;27:1171.
![Page 40: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/40.jpg)
Potential Urine Based Screening Opportunities
• Juvenile detention/jails• Emergency departments• High schools• General medicine clinics, especially teen clinics• Drug rehabilitation programs• Homeless clinics• Military induction centers
![Page 41: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/41.jpg)
Chlamydia Prevalence in High School Students by Age
14 15 16 17 18 190
2
4
6
8
10
12
14
16
Pre
vale
nce
(%)
Boys(n=1,625)
Girls(n=1,425)
![Page 42: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/42.jpg)
Age Specific Chlamydia Infection Rates in Washington State
Marrazzo JM, et al. Ann Intern Med 1977;127:796.
<15 15 16 17 18 19 20 >20
Age
0
5
10
15
20
Pre
vale
n ce
%
Girls Boys
![Page 43: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/43.jpg)
swab
Take the swab out of the sealed package
1
Remove the swab and hold it in the middle of the plastic handle
2
Carefully put the swab about two inches inside the opening of your vagina and gently turn the swab for 20 seconds. Make sure the swab touches the walls of your vagina
3
Remove the cap from the tube and put the swab into the tube so that you can see the tip is below the label
4
Carefully break the plastic handle against the side of the tube
5
Tightly screw the cap onto the tube. Follow the packaging instructions and mail the specimen
6
Vaginal Swab Study Specimen Collection Illustration
![Page 44: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/44.jpg)
Sensitivity of Different Specimens by Three Different Assays
Assay FCU Cx S-vag C-vag
TMA 72% 89% 93% 90%
PCR 84% 91% 91% 93%
LCR 98% 96% 98% 100%
Combined 81% 91% 93% 93%
FCU – first catch urine, Cx – endocervix, S-vag – self-collected vaginal swab, C-vag - Clinician collected vaginal swab. Schachter J, et al. STD 32;2005:725
![Page 45: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/45.jpg)
Testing Preference Survey Among 1090 Women Following a Pelvic
Examination and a SOVs Protocol
• 90% found self collection of vaginal swabs very easy and another 7% found it somewhat easy.
• 76% preferred a SOVs over a pelvic examination. 60% preferred it over a urine specimen.
• 94% said they would be tested for STIs more often is SOVs were available.
Chernesky MA, et al. Sex Transm Dis 32; 2005:729
![Page 46: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/46.jpg)
Penicillin and Tetracycline Resistance Among U.S. Gonococcal Isolates- 2000
SusceptiblePPNGTRNGPPNG/TRNGPenRTetRCMRNG
75.2%
1.6%
5.9%
0.6%
3.8%
5.1%
7.7%
![Page 47: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/47.jpg)
2006 CDC STD Treatment GuidelinesUncomplicated Gonococcal Infections
• Recommended RegimensCefixime 400 mg orally in a single dose
orCeftriaxone 125 mg IM in a single dose
orCiprofloxacin 500 mg orally in a single dose
orLevofloxacin 250 mg orally in a single dose
PLUS (If chlamydia not ruled out)Doxycycline 100 mg orally 2 times a day for 7 days or
Azithromycin 1 gm orally
![Page 48: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/48.jpg)
Percent of U.S. N. gonorrhoeae Isolates With Decreased Susceptibility or
Resistance to Ciprofloxacin, 1990–2000
Percent
Decreased susc.Resistance
0.0
0.4
0.8
1.2
1.6
2.0
1990 91 92 93 94 95 96 97 98 99 2000
![Page 49: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/49.jpg)
2006 CDC STD Treatment GuidelinesUncomplicated Gonococcal Infections
• Alternative Regimens
Spectinomycin 2 g IM single dose
Other single dose IM Cephalosporins (cefotaxime 500
mg, cefoxitin 2 g + probenecid, etc.)
Other single dose Quinolones (enoxacin 400 mg,
lomefloxacin 400 mg, norfloxacin 800 mg)
![Page 50: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/50.jpg)
2006 CDC STD Treatment Guidelines
Chlamydial Infections
• Recommended Regimens
Azithromycin 1 gram, orally, single dose
Doxycycline 100 mg orally 2 times a day for 7 days
![Page 51: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/51.jpg)
2006 CDC STD Treatment Guidelines
Nongonococcal Urethritis (NGU)
• Recommended Regimens
Azithromycin 1 gram, orally, single dose
Doxycycline 100 mg orally 2 times a day for 7 days
![Page 52: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/52.jpg)
2006 CDC STD Treatment Guidelines
Persistent or Recurrent NGU
Metronidazole 2 grams, orally, single dose
OR
Tinidazole 2 grams, orally, single dos
PLUS
Azithromycin 1 gram, orally, single dose (if not used previously)
![Page 53: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/53.jpg)
2006 CDC STD Treatment Guidelines
Chlamydial Infection During Pregnancy
• Recommended Regimens
Azithromycin 1 gram, orally, single dose
OR
Amoxicillin 500 mg orally 3 times daily
for 7 days
![Page 54: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/54.jpg)
2006 CDC STD Treatment Guidelines
Mild PID• Recommended Regimen B
Ceftriaxone 250 mg IM oncePLUS
Doxycycline 100 mg orally 2 times a day for 14 days
WITH OR WITHOUTMetronidazole 500 orally 2 times daily for 14 days
![Page 55: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/55.jpg)
Just a little sunshine…
![Page 56: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/56.jpg)
Just a little rain…
![Page 57: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/57.jpg)
Just a little pleasure…
![Page 58: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/58.jpg)
AND THEN….
![Page 59: Gonorrhea and Chlamydia David H. Martin, MD LSU Health Sciences Center Section of Infectious Diseases](https://reader035.vdocument.in/reader035/viewer/2022062409/56649ee65503460f94bf7406/html5/thumbnails/59.jpg)
Just a little PAIN!!